Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Total Liabilities (2016 - 2025)

Sanofi's Total Liabilities history spans 11 years, with the latest figure at -$83.1 billion for Q4 2025.

  • For Q4 2025, Total Liabilities changed 0.32% year-over-year to -$83.1 billion; the TTM value through Dec 2025 reached -$83.1 billion, changed 0.32%, while the annual FY2025 figure was -$80.6 billion, 3.87% up from the prior year.
  • Total Liabilities for Q4 2025 was -$83.1 billion at Sanofi, roughly flat from -$82.8 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at -$76.3 billion in Q4 2022 and bottomed at -$83.1 billion in Q4 2025.
  • The 5-year median for Total Liabilities is -$79.7 billion (2023), against an average of -$80.1 billion.
  • The largest annual shift saw Total Liabilities dropped 4.42% in 2021 before it rose 2.89% in 2022.
  • A 5-year view of Total Liabilities shows it stood at -$78.6 billion in 2021, then grew by 2.89% to -$76.3 billion in 2022, then dropped by 4.41% to -$79.7 billion in 2023, then fell by 3.97% to -$82.8 billion in 2024, then dropped by 0.32% to -$83.1 billion in 2025.
  • Per Business Quant, the three most recent readings for SNY's Total Liabilities are -$83.1 billion (Q4 2025), -$82.8 billion (Q4 2024), and -$79.7 billion (Q4 2023).